NCT03717688 (NEP) is a Phase 4 clinical trial of Entresto in Diabetes, sponsored by Nicolai Jacob Wewer Albrechtsen.

Who is sponsoring NCT03717688?

NCT03717688 is sponsored by Nicolai Jacob Wewer Albrechtsen.

What drugs are being tested in NCT03717688?

Interventions in NCT03717688: Entresto, Sitagliptin 100mg, Placebos.

What condition does NCT03717688 study?

NCT03717688 studies Diabetes, Heart Failure.

Is NCT03717688 still recruiting?

NCT03717688 is currently completed. Last updated 8 July 2019.

Last reviewed 2019-07-08 · How we verify

NCT03717688: NEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Neprilysin on Glucagon-like Peptide-1

Completed Phase 4 Last updated 8 July 2019

What this trial tests

Phase 4 trial testing Entresto in Diabetes in 19 participants. Completed in 14 May 2019.

Timeline

17 May 2018

Primary endpoint
1 February 2019

14 May 2019

Quick facts

Lead sponsor	Nicolai Jacob Wewer Albrechtsen
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	17 May 2018
Primary completion	1 February 2019
Estimated completion	14 May 2019
Sites	1 location across Denmark

Drugs / interventions tested

Entresto — full drug profile →
Sitagliptin 100mg — full drug profile →
Placebos — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Heart Failure — all drugs for Heart Failure →

Sponsor

Nicolai Jacob Wewer Albrechtsen

Who can join

Adults 18 to 30, male only, with Diabetes or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the current study we wish to investigate the effects on glucagon-like peptide-1 (GLP-1) of a neprilysin inhibitor

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism.
Kjeldsen SAS, Hansen LH, Esser N, Mongovin S, et al · · 2021 · cited 20× · PMID 34337276 · DOI 10.1210/jendso/bvab084
Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men.
Thonsgaard S, Prickett TCR, Hansen LH, Wewer Albrechtsen NJ, et al · · 2022 · cited 8× · PMID 35175317 · DOI 10.1093/clinchem/hvac005

Verify or expand the search:

Other trials of Entresto

Trials testing the same drug.

NCT05976230 — Special Drug Use Surveillance of Entresto Tablets (Hypertension) · completed
NCT04781881 — Special Drug Use Surveillance for Entresto Tablets · completed
NCT03553810 — Role of ARNi in Ventricular Remodeling in Hypertensive LVH · Phase 2 · completed
NCT03893526 — Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes · Phase 4 · completed
NCT03821701 — Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure · NA · unknown

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Nicolai Jacob Wewer Albrechtsen trials

Trials by the same sponsor.

NCT07350512 — Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants · NA · not yet recruiting
NCT06921824 — Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants · NA · completed
NCT06647368 — Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in · NA · recruiting
NCT03520062 — The Effect of Liraglutide on Pancreatic Hormones and Its Size · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03717688 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nicolai Jacob Wewer Albrechtsen
Last refreshed: 8 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03717688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing